Stocktoria
Sunshine Biopharma Inc. SBFM
Sunshine Biopharma Inc. (SBFM) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $36.3M at a -16.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.89 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.679 |
| Retained earnings / assets | -2.494 |
| EBIT / assets | -0.207 |
| Equity / liabilities | 3.272 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SBFM | Sunshine Biopharma Inc. | 4/9 | -1.63 | — | +4.1% |
| ETST | Earth Science Tech, Inc. | 4/9 | — | 12.7 | +7.8% |
| VRCA | Verrica Pharmaceuticals Inc. | 5/9 | -19.42 | — | — |
| BGM | BGM Group Ltd. | 5/9 | 7.99 | — | +51.1% |
| ZOMDF | Zomedica Corp. | 3/9 | 1.07 | — | +17.4% |
| VSTM | Verastem, Inc. | 4/9 | -15.71 | — | +209.1% |
| FHTX | Foghorn Therapeutics Inc. | 1/9 | -10.28 | — | +36.8% |
About Sunshine Biopharma Inc.
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
FAQ
Is SBFM financially healthy?
Sunshine Biopharma Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does SBFM pay a dividend?
No, Sunshine Biopharma Inc. does not currently pay a dividend.
How profitable is SBFM?
In FY2025, Sunshine Biopharma Inc. had a net margin of -16.5% and a return on equity of -25.9%.
What is the analyst price target for SBFM?
The average Wall-Street price target for Sunshine Biopharma Inc. is $56.00, about 4528.1% above the recent price, from 1 analysts.
Is SBFM a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Sunshine Biopharma Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.